PHARMAC publishes clinical expert advice on nivolumab (Opdivo)

May 19, 2016

PHARMAC notification

The advice from the clinical experts that advise PHARMAC has now been published.   The advice relates to new proposed treatments, including nivolumab (Opdivo) for advanced melanoma.

The advice includes the following:

  • The minute of the Pharmacology and Therapeutics Advisory Committee’s (PTAC) consideration of the funding application for nivolumab for advanced melanoma from their May meeting
  • The minute of the Cancer Treatments Subcommittee of PTAC’s consideration of the application from their April  meeting.

These minutes can be found on the nivolumab consultation page, or the application tracker, on the PHARMAC website.

PHARMAC is seeking feedback on the funding proposal by 5pm on 25 May 2016.

According to PHARMAC, final decisions will be made by the PHARMAC Board in time for implementation from as early as 1 July 2016.


« Back to News